CO5690551A2 - Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo - Google Patents
Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismoInfo
- Publication number
- CO5690551A2 CO5690551A2 CO06031620A CO06031620A CO5690551A2 CO 5690551 A2 CO5690551 A2 CO 5690551A2 CO 06031620 A CO06031620 A CO 06031620A CO 06031620 A CO06031620 A CO 06031620A CO 5690551 A2 CO5690551 A2 CO 5690551A2
- Authority
- CO
- Colombia
- Prior art keywords
- thioxy
- haloalkylsulfinyl
- haloalkylsulfonyl
- alkylsulfinyl
- haloalkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un compuesto de Fórmula (I): en la cual: X es NH o O;R1 se selecciona del grupo integrado por H, halógeno, hidroxi, tioxi, ciano, nitro, haloalquilo C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-5, haloalcoxi C1-4, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, haloalquiltio C1-4, haloalquilsulfinilo C1-4 y haloalquilsulfonilo C1-4;R2 se selecciona del grupo integrado por H, halógeno, hidroxi, tioxi, ciano, nitro, haloalquilo C1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-5, haloalcoxi C1-4, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, haloalquiltio C1-4, haloalquilsulfinilo C1-4 y haloalquilsulfonilo C1-4; o R2 está ausente;- - - es un enlace simple cuando R2 está presente, o - - - es un doble enlace cuando R2 está ausente; y El Anillo A es un anillo carbocíclico de 5, 6 o 7 miembros o un anillo heterocíclico de 5, 6 o 7 miembros opcionalmente sustituido con 1 a 4 sustituyentes seleccionados del grupo integrado por halógeno, hidroxi, tioxi, ciano, nitro, haloalquiloC1-4, amino, alquilamino C1-4, dialquilamino C2-8, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-5, haloalcoxi C1-4, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, haloalquiltio C1-4, haloalquilsulfinilo C1-4 y haloalquilsulfonilo C1-4; o su sal, solvato o hidrato aceptable para uso farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51623803P | 2003-10-31 | 2003-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5690551A2 true CO5690551A2 (es) | 2006-10-31 |
Family
ID=34572875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06031620A CO5690551A2 (es) | 2003-10-31 | 2006-03-30 | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo |
Country Status (38)
Country | Link |
---|---|
US (2) | US8637555B2 (es) |
EP (2) | EP1683794A1 (es) |
JP (2) | JP4533898B2 (es) |
KR (1) | KR100850591B1 (es) |
CN (1) | CN1867562B (es) |
AR (1) | AR046611A1 (es) |
AT (1) | ATE328880T1 (es) |
AU (1) | AU2004287861B2 (es) |
BR (1) | BRPI0415631A (es) |
CA (1) | CA2539985C (es) |
CO (1) | CO5690551A2 (es) |
CR (1) | CR8270A (es) |
CY (1) | CY1105479T1 (es) |
DE (1) | DE602004001134T2 (es) |
DK (1) | DK1599469T3 (es) |
EA (1) | EA011484B1 (es) |
EC (1) | ECSP066529A (es) |
ES (1) | ES2267077T3 (es) |
GE (1) | GEP20094801B (es) |
HK (1) | HK1076468A1 (es) |
HR (1) | HRP20060286T3 (es) |
IL (1) | IL174042A0 (es) |
IS (1) | IS2372B (es) |
MA (1) | MA28171A1 (es) |
MX (1) | MXPA06004556A (es) |
MY (1) | MY140410A (es) |
NO (1) | NO20062509L (es) |
NZ (1) | NZ546285A (es) |
PE (1) | PE20050483A1 (es) |
PL (1) | PL1599469T3 (es) |
PT (1) | PT1599469E (es) |
RS (1) | RS20060290A (es) |
SI (1) | SI1599469T1 (es) |
TN (1) | TNSN06150A1 (es) |
TW (1) | TWI258478B (es) |
UA (1) | UA86783C2 (es) |
WO (1) | WO2005044816A1 (es) |
ZA (2) | ZA200603419B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
ES2331521T3 (es) | 2003-11-21 | 2010-01-07 | Arena Pharmaceuticals, Inc. | Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo. |
US20070244107A1 (en) * | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
EP1811996A1 (en) * | 2004-11-05 | 2007-08-01 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
EP1877402A1 (en) | 2005-04-28 | 2008-01-16 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
PT1901731E (pt) | 2005-06-28 | 2011-05-11 | Merck Sharp & Dohme | Agonistas de receptor de niacina, composi??es que cont?m tais compostos e m?todos de tratamento |
DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
MX2015010725A (es) | 2013-02-21 | 2016-05-31 | Adverio Pharma Gmbh | Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato. |
WO2015012210A1 (ja) * | 2013-07-23 | 2015-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ縮合環化合物 |
CN103755637A (zh) * | 2013-12-26 | 2014-04-30 | 平湖优康药物研发有限公司 | 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺 |
US20210110275A1 (en) * | 2019-10-11 | 2021-04-15 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02178263A (ja) * | 1988-12-27 | 1990-07-11 | Kaken Pharmaceut Co Ltd | アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤 |
US5134155A (en) * | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
EA003056B1 (ru) | 1996-12-23 | 2002-12-26 | Дюпон Фармасьютикалз Компани | АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ |
KR100620337B1 (ko) | 1998-03-10 | 2006-09-13 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제 |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
RU2259998C2 (ru) | 2000-03-09 | 2005-09-10 | Оно Фармасьютикал Ко., Лтд. | Производные индола, способ их получения и их применение |
US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
US6699997B2 (en) | 2000-06-28 | 2004-03-02 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
CZ300945B6 (cs) | 2000-06-30 | 2009-09-23 | Glaxo Group Limited | Zpusob prípravy 5-(6-chinazolinyl)-furan-2-karbaldehydu |
US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
EP1395590B1 (en) | 2001-05-23 | 2006-09-27 | Merck Frosst Canada & Co. | Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists |
CN1245391C (zh) | 2001-06-01 | 2006-03-15 | 弗·哈夫曼-拉罗切有限公司 | 用作谷氨酸受体的嘧啶、三嗪和吡嗪衍生物 |
WO2003002544A1 (en) | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
EP1292602B1 (en) | 2001-06-27 | 2004-04-07 | RS Tech Corp. | New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst |
CA2459515A1 (en) | 2001-09-07 | 2003-03-20 | Kazuhiko Torisu | Indole derivatives |
DE10148617A1 (de) | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
ATE516277T1 (de) | 2002-03-19 | 2011-07-15 | Ono Pharmaceutical Co | Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
WO2004032928A1 (en) * | 2002-10-10 | 2004-04-22 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
DE10261131A1 (de) | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20070032537A1 (en) | 2003-06-13 | 2007-02-08 | Arena Pharmaceuticals, Inc. | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases |
GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
GB0319124D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
PE20050483A1 (es) * | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
AU2005212816C1 (en) | 2004-02-14 | 2010-03-04 | Glaxosmithkline Llc | Novel compounds |
US20070244107A1 (en) | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
EP1811996A1 (en) | 2004-11-05 | 2007-08-01 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
EP1877402A1 (en) | 2005-04-28 | 2008-01-16 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
-
2004
- 2004-10-27 PE PE2004001031A patent/PE20050483A1/es not_active Application Discontinuation
- 2004-10-27 TW TW093132486A patent/TWI258478B/zh not_active IP Right Cessation
- 2004-10-28 MY MYPI20044462A patent/MY140410A/en unknown
- 2004-10-29 EP EP06005248A patent/EP1683794A1/en not_active Withdrawn
- 2004-10-29 EA EA200600879A patent/EA011484B1/ru not_active IP Right Cessation
- 2004-10-29 DE DE602004001134T patent/DE602004001134T2/de active Active
- 2004-10-29 PT PT04818324T patent/PT1599469E/pt unknown
- 2004-10-29 GE GEAP20049421A patent/GEP20094801B/en unknown
- 2004-10-29 CN CN2004800299376A patent/CN1867562B/zh not_active Expired - Fee Related
- 2004-10-29 CA CA2539985A patent/CA2539985C/en not_active Expired - Fee Related
- 2004-10-29 AU AU2004287861A patent/AU2004287861B2/en not_active Ceased
- 2004-10-29 KR KR1020067008311A patent/KR100850591B1/ko not_active IP Right Cessation
- 2004-10-29 WO PCT/US2004/035927 patent/WO2005044816A1/en active IP Right Grant
- 2004-10-29 AR ARP040103978A patent/AR046611A1/es unknown
- 2004-10-29 UA UAA200605989A patent/UA86783C2/ru unknown
- 2004-10-29 RS YUP-2006/0290A patent/RS20060290A/sr unknown
- 2004-10-29 ES ES04818324T patent/ES2267077T3/es active Active
- 2004-10-29 NZ NZ546285A patent/NZ546285A/en not_active IP Right Cessation
- 2004-10-29 DK DK04818324T patent/DK1599469T3/da active
- 2004-10-29 US US10/535,345 patent/US8637555B2/en not_active Expired - Fee Related
- 2004-10-29 JP JP2006536942A patent/JP4533898B2/ja not_active Expired - Fee Related
- 2004-10-29 EP EP04818324A patent/EP1599469B1/en not_active Not-in-force
- 2004-10-29 AT AT04818324T patent/ATE328880T1/de active
- 2004-10-29 PL PL04818324T patent/PL1599469T3/pl unknown
- 2004-10-29 MX MXPA06004556A patent/MXPA06004556A/es active IP Right Grant
- 2004-10-29 BR BRPI0415631-5A patent/BRPI0415631A/pt not_active IP Right Cessation
- 2004-10-29 SI SI200430058T patent/SI1599469T1/sl unknown
-
2005
- 2005-12-06 HK HK05111162A patent/HK1076468A1/xx not_active IP Right Cessation
-
2006
- 2006-03-01 IL IL174042A patent/IL174042A0/en unknown
- 2006-03-03 CR CR8270A patent/CR8270A/es not_active Application Discontinuation
- 2006-03-30 CO CO06031620A patent/CO5690551A2/es not_active Application Discontinuation
- 2006-04-28 EC EC2006006529A patent/ECSP066529A/es unknown
- 2006-04-28 ZA ZA200603419A patent/ZA200603419B/en unknown
- 2006-05-22 TN TNP2006000150A patent/TNSN06150A1/en unknown
- 2006-05-23 MA MA29049A patent/MA28171A1/fr unknown
- 2006-05-24 IS IS8481A patent/IS2372B/is unknown
- 2006-05-31 NO NO20062509A patent/NO20062509L/no not_active Application Discontinuation
- 2006-07-26 ZA ZA200606203A patent/ZA200606203B/xx unknown
- 2006-08-24 HR HR20060286T patent/HRP20060286T3/xx unknown
- 2006-09-05 CY CY20061101259T patent/CY1105479T1/el unknown
- 2006-11-17 US US11/601,252 patent/US20070072924A1/en not_active Abandoned
-
2010
- 2010-03-10 JP JP2010053852A patent/JP2010163448A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
DE60322359D1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
CY1107001T1 (el) | Αζωτουχα ετεροκυκλικα παραγωγα καρβοξαμιδιου ή αλας αυτων ως αντιϊκοι παραγοντες | |
DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
EA200201179A1 (ru) | Производные 2-аминокарбонил-9h-пурина | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
WO2007146124A3 (en) | Deuterated tadalafil derivatives | |
AR063625A1 (es) | COMPUESTOS HETEROCICLICOS eTILES COMO AGENTES ANTICANCEROSOS | |
AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
AR043673A1 (es) | Compuestos heterociclicos inhibidores no nucleosidos de la transcriptasa inversa i, preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del sida | |
DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
EA200970124A1 (ru) | Производные 2-арилиндола в качестве ингибиторов npges-1 | |
ATE359791T1 (de) | Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer | |
EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение | |
RS53211B (en) | PYRIDO [2,3-d] PYRIMIDINE DERIVATIVES, THEIR PRODUCTION, THEIR USE IN THERAPY | |
DE60336735D1 (de) | Neue biologischaktive molekü le | |
RS20060072A (en) | Aminoquinoline derivatives and their use as adenosine a3 ligands | |
AR056087A1 (es) | Derivados de azetidina como antagonistas de receptores de neuroquina nk | |
NO20090332L (no) | 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |